CVS Strikes Deal for Repatha Only; 18,000 Enroll in Long-term Praluent CV Outcomes Trial
CVS Health Corp. announced Monday that it will add Amgen’s evolocumab, being marketed as Repatha, to its formulary, opting to cover just 1 and not both of the recently approved cholesterol-fighting PCSK9 inhibitors to its formulary. Terms of the deal were not announced.
The move comes about 6 weeks after Express Scripts, the nation’s largest pharmacy benefits manager, announced it would cover both evolocumab and alirocumab, being marketed as Praluent by Sanofi and Regeneron. Terms of those deals were not disclosed. FDA approved the 2 injectable therapies were approved this summer after clinical trials showed they could reduce low-density lipoprotein (LDL) cholesterol levels by 60%.
